PMID- 31704869
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20200108
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 11
DP  - 2019 Nov
TI  - Impact of Acridine Orange in Patients With Soft Tissue Sarcoma Treated With 
      Marginal Resection.
PG  - 6365-6372
LID - 10.21873/anticanres.13849 [doi]
AB  - BACKGROUND/AIM: Although few studies have shown the effectiveness of adjuvant 
      therapy with acridine orange (AO) for soft tissue sarcoma (STS) patients, no 
      study has investigated this among cases with marginal resection. The aim of the 
      study was to evaluate the effectiveness of AO therapy directly by comparing it to 
      marginal resection cases that did not receive AO. PATIENTS AND METHODS: This 
      retrospective study included 19 and 33 patients with STS who received AO therapy 
      (AO group) and marginal resection without AO therapy (non-AO group), 
      respectively. The patients' clinical information was collected, and the clinical 
      courses were compared. RESULTS: The local recurrence rate in the AO group was 
      significantly lower than that in the non-AO group (p<0.05). The local 
      recurrence-free survival curves significantly differed between the two groups 
      (p<0.05). High grade malignancy and no treatment with AO were identified as risk 
      factors for local recurrence (p<0.05). CONCLUSION: AO therapy strongly suppressed 
      local recurrence after marginal resection of STS.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Tsuchie, Hiroyuki
AU  - Tsuchie H
AUID- ORCID: 0000-0001-5011-7184
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan tuchikiti@yahoo.co.jp.
FAU - Emori, Makoto
AU  - Emori M
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Miyakoshi, Naohisa
AU  - Miyakoshi N
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Nagasawa, Hiroyuki
AU  - Nagasawa H
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Okada, Kyoji
AU  - Okada K
AD  - Department of Physical Therapy, Akita University Graduate School of Health 
      Sciences, Akita, Japan.
FAU - Murahashi, Yasutaka
AU  - Murahashi Y
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Mizushima, Emi
AU  - Mizushima E
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Shimizu, Junya
AU  - Shimizu J
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Yamashita, Toshihiko
AU  - Yamashita T
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Shimada, Yoichi
AU  - Shimada Y
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Fluorescent Dyes)
RN  - F30N4O6XVV (Acridine Orange)
SB  - IM
MH  - Acridine Orange/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents
MH  - Case-Control Studies
MH  - Combined Modality Therapy/methods
MH  - Disease-Free Survival
MH  - Female
MH  - Fluorescent Dyes/*therapeutic use
MH  - Humans
MH  - Male
MH  - *Margins of Excision
MH  - Middle Aged
MH  - *Neoplasm Recurrence, Local/prevention & control
MH  - Retrospective Studies
MH  - Sarcoma/*drug therapy/pathology/*surgery
OTO - NOTNLM
OT  - Acridine orange
OT  - marginal resection
OT  - soft tissue sarcoma
EDAT- 2019/11/11 06:00
MHDA- 2019/11/15 06:00
CRDT- 2019/11/10 06:00
PHST- 2019/09/04 00:00 [received]
PHST- 2019/09/19 00:00 [revised]
PHST- 2019/09/23 00:00 [accepted]
PHST- 2019/11/10 06:00 [entrez]
PHST- 2019/11/11 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
AID - 39/11/6365 [pii]
AID - 10.21873/anticanres.13849 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Nov;39(11):6365-6372. doi: 10.21873/anticanres.13849.